High-dose ω-3 Fatty Acid Plus Vitamin D3 Supplementation Affects Clinical Symptoms and Metabolic Status of Patients with Multiple Sclerosis: A Randomized Controlled Clinical Trial
The Journal of Nutrition, nxy116, https://doi.org/10.1093/jn/nxy116
Ebrahim Kouchaki Maryam Afarini Javad Abolhassani Naghmeh Mirhosseini Fereshteh Bahmani Seyed Ali Masoud Zatollah Asemi
Short 12 week trial using 50,000 IU of vitamin D bi-weekly
In conjuction with 2 × 1000 mg/d ω-3 fatty acid (we assume the Omega-3 was daily)
This was a radomized controlled trial of Vit D + Omega-3 vs placebo
Nice to see trials like this starting to use more than monotherapy
( e.g. just Vitamin D OR just Omega-3)
Would expect even more benefit if trial had lasted longer - say 6 months
Would expect even more benefit if trial had used more vitamin D
Note: MS has been cured in > 2,000 people with daily doses ranging from 20,000 - 140,000 IU
= approximately 140,000 - 1,960,000 IU if given bi-weekly
= 3X - 39X more Vitamin D than used in this study
- Overview MS and vitamin D
- Multiple Sclerosis treated when use high doses of vitamin D – meta-analysis May 2018
- Multiple Sclerosis: number needed to treat with vitamin D may be as low as 1.3 – Meta-analysis Oct 2013
- Multiple Sclerosis risk increased due to genes - 22nd study – Aug 2017
- Multiple Sclerosis relapses cut in half by bi-weekly 100,000 IU of Vitamin D – RCT 2019
UV and Sunshine reduces MS risk
- Multiple Sclerosis 2X more likely if low winter UV – June 2018
- Multiple Sclerosis half as likely if get plenty of sunshine (not a news item) – March 2018
Other things also help
- Multiple Sclerosis treated by 50,000 IU Vitamin D bi-weekly plus Omega-3 – RCT July 2018
- Multiple Sclerosis 40 percent less likely if consume tinned fish (Vitamin D and Omega-3) – Sept 2019
- Resveratrol treats Multiple Sclerosis and other autoimmune diseases – many studies
- Not a single case of multiple sclerosis in 15,000,000 people (plant-based diets)
High Dose Vitamin D and cofactors
- The use of high dose Vitamin D (Coimbra Protocol) for multiple sclerosis in Germany – 2019
- Successful high dose vitamin D (Coimbra Protocol) should be evaluated – June 2019
- Comparing High-dose vitamin D therapies MS and other health problems
Number of MS studies which are also in other categories
20 studies in Genetics - genes can restrict Vitamin D getting to the blood and to the cells 10 studies in Vitamin D Receptor - gene which restricts D from getting to the cells 5 studies in Vitamin D Binding Protein - gene which restricts D from getting to the cells 19 studies in Ultraviolet light - may be even better than Vitamin D in preventing and treating MS 9 studies in Omega-3 - which helps Vitamin D prevent and treat MS
Background: Combined omega-3 fatty acid and vitamin D supplementation may improve multiple sclerosis (MS) by correcting metabolic abnormalities and attenuating oxidative stress and inflammation.
Objective: This study aimed to determine the effects of ω-3 fatty acid and vitamin D cosupplementation on the disability score and metabolic status of patients with MS.
This was a randomized, placebo-controlled clinical trial with Expanded Disability Status Scale (EDSS) score and inflammation as primary outcomes and oxidative stress biomarkers and metabolic profile as secondary outcomes. Patients, aged 18–55 y, were matched for disease EDSS scores, gender, medications, BMI, and age (n = 53) and randomly received a combined 2 × 1000 mg/d ω-3 fatty acid and 50,000 IU/biweekly cholecalciferol supplement or placebo for 12 wk. The placebos were matched in colour, shape, size, packaging, smell, and taste with supplements. Fasting blood samples were collected at baseline and end of intervention to measure different outcomes. Multiple linear regression models were used to assess treatment effects on outcomes adjusting for confounding variables.
Patients taking ω-3 fatty acid plus vitamin D supplements showed a significant improvement in
- EDSS (β −0.18; 95% CI: −0.33, −0.04; P = 0.01), compared with placebo.
- Serum high-sensitivity C-reactive protein (β −1.70 mg/L; 95% CI: −2.49, −0.90 mg/L; P < 0.001),
- plasma total antioxidant capacity (β +55.4 mmol/L; 95% CI: 9.2, 101.6 mmol/L; P = 0.02),
- total glutathione (β +51.14 µmol/L; 95% CI: 14.42, 87.87 µmol/L; P = 0.007), and
- malondialdehyde concentrations (β −0.86 µmol/L; 95% CI: −1.10, −0.63 µmol/L; P < 0.001)
were significantly improved in the supplemented group compared with the placebo group.
In addition, ω-3 fatty acid and vitamin D cosupplementation resulted in a significant reduction in
- serum insulin,
- insulin resistance, and
and a significant increase in
- insulin sensitivity and
- serum HDL-cholesterol concentrations.
Overall, taking ω-3 fatty acid and vitamin D supplements for 12 wk by patients with MS had beneficial effects on EDSS and metabolic status.
This trial was registered at the Iranian website (www.irct.ir) for registration of clinical trials as IRCT2017090133941N20.